Yersinia pestis infection future or investigational therapies: Difference between revisions
No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Yersinia pestis infection}} | {{Yersinia pestis infection}} | ||
{{CMG}}; {{AE}} {{JS}} | |||
==Overview== | |||
<!-- | |||
Research is under way to develop improved plague vaccines that are likely to be protective against airborne infection and could be administered as inhalants.66,67 At present, the most promising candidates are recombi- nant subunit vaccines that express F1 and V antigens of Y. pestis and seem to protect animals against infective aerosol exposures.68-70 A wide variety of other approaches are also under investigation, including passive immunization with aerosolized monoclonal antibodies71 and vaccines based on attenuated Y. pseudotuberculosis.72,73 | |||
--> | |||
==References== | ==References== | ||
Revision as of 19:18, 25 July 2014
|
Yersinia pestis infection Microchapters |
|
Differentiating Yersinia Pestis Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Yersinia pestis infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Yersinia pestis infection future or investigational therapies |
|
FDA on Yersinia pestis infection future or investigational therapies |
|
CDC on Yersinia pestis infection future or investigational therapies |
|
Yersinia pestis infection future or investigational therapies in the news |
|
Blogs on Yersinia pestis infection future or investigational therapies |
|
Risk calculators and risk factors for Yersinia pestis infection future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]